share_log

Nuvectis Pharma Analyst Ratings

Benzinga ·  Sep 15, 2023 06:09
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
09/15/2023 49.79% HC Wainwright & Co. → $21 Reiterates Buy → Buy
03/07/2023 49.79% HC Wainwright & Co. → $21 Reiterates → Buy
02/10/2023 49.79% HC Wainwright & Co. → $21 Reiterates → Buy
07/13/2022 49.79% Ladenburg Thalmann → $21 Initiates Coverage On → Buy
05/10/2022 49.79% HC Wainwright & Co. $14 → $21 Maintains Buy
03/02/2022 -0.14% HC Wainwright & Co. → $14 Initiates Coverage On → Buy

What is the target price for Nuvectis Pharma (NVCT)?

The latest price target for Nuvectis Pharma (NASDAQ: NVCT) was reported by HC Wainwright & Co. on September 15, 2023. The analyst firm set a price target for $21.00 expecting NVCT to rise to within 12 months (a possible 49.79% upside). 3 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Nuvectis Pharma (NVCT)?

The latest analyst rating for Nuvectis Pharma (NASDAQ: NVCT) was provided by HC Wainwright & Co., and Nuvectis Pharma reiterated their buy rating.

When is the next analyst rating going to be posted or updated for Nuvectis Pharma (NVCT)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nuvectis Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nuvectis Pharma was filed on September 15, 2023 so you should expect the next rating to be made available sometime around September 15, 2024.

Is the Analyst Rating Nuvectis Pharma (NVCT) correct?

While ratings are subjective and will change, the latest Nuvectis Pharma (NVCT) rating was a reiterated with a price target of $0.00 to $21.00. The current price Nuvectis Pharma (NVCT) is trading at is $14.02, which is within the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment